ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,441 to 4,460 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
HZ/su Group vs Placebo Group: Number of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine1 of 714

1 of 712

-0.0 points

-0.7 to 0.7

1,426NCT04091451

Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster

HZ/su Group vs Placebo Group: deaths from any cause12 of 714

8 of 712

0.6 points

-0.7 to 1.9

1,426NCT04091451

Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster

HZ/su Group vs Placebo Group: serious adverse events56 of 714

43 of 712

1.8 points

-0.9 to 4.5

1,426NCT04091451

Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster

Restrictive vs Liberal: serious adverse events386 of 712

372 of 712

2.0 points

-3.2 to 7.1

1,424NCT03229941

Transfusion Trigger After Operations in High Cardiac Risk Patients

Intervention vs Control: Facility-level Inappropriate Prostate Cancer Bone Scan Imaging Rates109 of 734

141 of 690

-5.6 points

-9.6 to -1.6

1,424NCT03445559

A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging

STS101 5.2 mg vs STS101 Placebo: Percentage of Subjects With Freedom From Most-Bothersome Symptom at 2 Hours Post Dose265 of 716

230 of 708

4.5 points

-0.4 to 9.4

1,424NCT04940390

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

STS101 5.2 mg vs STS101 Placebo: Percentage of Subjects With Freedom From Migraine Headache Pain at 2 Hours Post Dose146 of 716

124 of 708

2.9 points

-1.2 to 6.9

1,424NCT04940390

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

STS101 5.2 mg vs STS101 Placebo: Percentage of Subjects With Relief From Migraine Headache Pain at 2 Hours Post Dose379 of 716

316 of 708

8.3 points

3.1 to 13.4

1,424NCT04940390

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

Candesartan vs Placebo: Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.178 of 711

217 of 710

-5.5 points

-10.2 to -0.9

1,421NCT00252733

Diabetic Retinopathy Candesartan Trials

Oracea® as Monotherapy vs Oracea® as add-on Therapy: Number of Treatment Responders at Endpoint, Where Response is Defined as an IGA Score of 0 (Clear) or 1 (Near Clear)616 of 1,197

106 of 224

4.1 points

-3.0 to 11.2

1,421NCT00892281

ORCA - Oracea® for Rosacea: A Community-based Assessment

Dabigatran (Dabigatran vs VKA) vs Vitamin K Antagonists (VKA): deaths from any cause10 of 771

5 of 650

0.5 points

-0.6 to 1.7

1,421NCT02240667

Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)

Dabigatran (Dabigatran vs VKA) vs Vitamin K Antagonists (VKA): serious adverse events45 of 771

39 of 650

-0.2 points

-2.7 to 2.3

1,421NCT02240667

Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)

Candesartan vs Placebo: serious adverse events102 of 710

112 of 710

-1.4 points

-5.1 to 2.3

1,420NCT00252733

Diabetic Retinopathy Candesartan Trials

Oracea® as Monotherapy vs Oracea® as add-on Therapy: serious adverse events5 of 1,196

0 of 224

0.4 points

-1.3 to 1.0

1,420NCT00892281

ORCA - Oracea® for Rosacea: A Community-based Assessment

Video Laryngoscope Group vs Direct Laryngoscope Group: Operator-reported Aspiration7 of 705

12 of 712

-0.7 points

-2.0 to 0.6

1,417NCT05239195

DirEct Versus VIdeo LaryngosCopE Trial

Video Laryngoscope Group vs Direct Laryngoscope Group: Number of Participants With Severe Complications of Tracheal Intubation151 of 705

149 of 712

0.5 points

-3.8 to 4.7

1,417NCT05239195

DirEct Versus VIdeo LaryngosCopE Trial

Video Laryngoscope Group vs Direct Laryngoscope Group: All-cause In-hospital Mortality184 of 705

191 of 712

-0.7 points

-5.3 to 3.9

1,417NCT05239195

DirEct Versus VIdeo LaryngosCopE Trial

Video Laryngoscope Group vs Direct Laryngoscope Group: Injury to the Teeth3 of 705

2 of 712

0.1 points

-0.6 to 1.0

1,417NCT05239195

DirEct Versus VIdeo LaryngosCopE Trial

Video Laryngoscope Group vs Direct Laryngoscope Group: Number of Intubations With Successful Intubation on the First Attempt600 of 705

504 of 712

14.3 points

10.0 to 18.5

1,417NCT05239195

DirEct Versus VIdeo LaryngosCopE Trial

Video Laryngoscope Group vs Direct Laryngoscope Group: Successful Intubation on the First Attempt Without a Severe Complication484 of 705

420 of 712

9.7 points

4.7 to 14.6

1,417NCT05239195

DirEct Versus VIdeo LaryngosCopE Trial

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=223"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=223

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04091451-9af7180d",
        "title": "HZ/su Group vs Placebo Group: Number of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine",
        "summary": "1 of 714 against 1 of 712; risk difference -0.0 points, 95% interval -0.7 to 0.7; NCT04091451, Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster",
        "record": "/library/comparisons/NCT04091451-9af7180d",
        "nct_id": "NCT04091451",
        "kind": "outcome",
        "participants": 1426,
        "risk_difference": {
          "value": -0.000003934157932836005,
          "lower": -0.0066131379131841575,
          "upper": 0.006588009024119329
        },
        "group_1": "1 of 714",
        "group_2": "1 of 712",
        "difference": "-0.0 points",
        "interval": "-0.7 to 0.7",
        "trial_title": "Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster"
      },
      {
        "id": "NCT04091451-deaths",
        "title": "HZ/su Group vs Placebo Group: deaths from any cause",
        "summary": "12 of 714 against 8 of 712; risk difference 0.6 points, 95% interval -0.7 to 1.9; NCT04091451, Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster",
        "record": "/library/comparisons/NCT04091451-deaths",
        "nct_id": "NCT04091451",
        "kind": "deaths",
        "participants": 1426,
        "risk_difference": {
          "value": 0.0055707676328958546,
          "lower": -0.007372152170508749,
          "upper": 0.019092478805890496
        },
        "group_1": "12 of 714",
        "group_2": "8 of 712",
        "difference": "0.6 points",
        "interval": "-0.7 to 1.9",
        "trial_title": "Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=224",
  "request_id": "XLSY4618YQai9MgA"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?